Physician Referrals to Sunstone

Sunstone Therapies offers psychedelic-assisted therapies as part of FDA-approved clinical studies to address a range of patient-specific diagnoses. Therapeutic options include various psychedelic medicines such as psilocybin, MDMA, LSD, and 5-MeO DMT.  Indications we are focusing on are Adjustment Disorder, Generalized Anxiety Disorder, Major Depressive Disorder, Post-Traumatic Stress Disorder, End of Life, and Treatment-Resistant Depression. Absolute Contraindications: Personal or family history of Bipolar Disorder, Schizophrenia, Borderline Personality Disorder, Delusional Disorder, current symptoms of Obsessive-Compulsive Disorder

Sunstone’s clinical team comprises licensed mental health professionals, including psychologists, psychiatrists, clinical counselors, and social workers, as well as physicians, experienced research staff, and medical assistants. Our therapists are trained to deliver psychedelic-assisted therapy with clinical precision and provide structured support throughout the preparation and integration process. Our multidisciplinary team brings more than 100 years of combined clinical and research experience. Team members hold positions at leading institutions, including the Johns Hopkins Center for Psychedelic and Consciousness Research and the Dana-Farber Cancer Institute, and have contributed to peer-reviewed journals such as JAMA Oncology, the Journal of Psychopharmacology, and the Journal of Palliative Medicine. Sunstone staff are actively shaping the future of psychedelic medicine—contributing to national standards for therapist training, board certification, CPT coding, and patient care guidelines.

Sunstone Therapies delivers psychedelic-assisted therapy grounded in both emerging and established clinical research. As the field evolves, so does our practice. Through ongoing collaboration, training, and reflection, our team continually refines its approach to supporting patients across preparation, dosing, and integration, aligning with best practices and evolving standards of care.

Psychedelic-assisted therapy involves distinct risks and benefits, and patients are fully informed through a structured consent and screening process. Therapists use psychometrically validated measures in conjunction with clinical interviews to assess appropriateness and identify potential contraindications. Ongoing communication with referring providers helps ensure continuity of care and supports informed, collaborative decision-making.

Sunstone Therapies provides resources to support patients in continuing their integration process after participating in a clinical trial. Our therapists may recommend supportive materials or connections based on individual needs. Additional community-based integration offerings are under development as part of Sunstone’s evolving model of care.